Forensic Analysis of Deaths in Pfizer-BioNTech COVID-19 Vaccine Trials

Many Deaths Occurred after Data Analysis Cutoff--Concealing Cardiovascular Death Signal from FDA VRBPAC

By Peter A. McCullough, MD, MPH

A new analysis from Michels et al has found that many deaths in the Pfizer-BioNTech COVID-19 Vaccine Trials program occurred after the data cutoff used to create the briefing booklet reviewed by the FDA CBER Vaccines and Related Biological Products Advisory Committee (VRBPAC) on December 10, 2020. This effectively concealed mortality data from the approval decision by the EUA mechanism.

Michels report suggest Pfizer was aware and busily working on the case report forms of these deaths coming in from the clinical trial sites: “In many of these 38 cases, the documentation provided in the CRF did not adequately support the cause of death diagnosis or did not allow one to rule out the possibility of a cardiovascular event with an autopsy. Frequent communications between Pfizer/BioNTech physicians and trial site medical staff are obvious in the CRFs, which were often quite lengthy some well over 400 to 900 pages.”